Telo Genomics Corp.

Recent News

  • Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

    Toronto, Ontario--(Newsfile Corp. - September 14, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma ("SMM"), in collaboration with the Mayo Clinic, has completed review and analysis of its first cohort, consisting of 187 patients and has exceeded its targeted endpoints.In July 2022, the Company announced that it had completed processing of the patient samples related to...

    2022-09-14 8:45 AM EDT
  • Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples

    Toronto, Ontario--(Newsfile Corp. - August 17, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces the completion of the laboratory processing and analysis of patient samples related to its multiple myeloma drug resistance clinical study. The patient samples were provided by the Mayo Clinic as part of an ongoing collaboration to evaluate the Company's prognostic technology for multiple myeloma ("MM"). TELO's study results have now been submitted back to the Mayo Clinic for review and...

    2022-08-17 8:45 AM EDT
  • Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma

    Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has commenced the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma ("MM") patients that are at high-risk of developing treatment resistance. This study is the second study being carried out in collaboration with the Mayo Clinic to evaluate the Company's prognostic technology to address multiple unmet clinical needs in MM.MM...

    2022-07-13 8:45 AM EDT
  • Telo Genomics Completes Processing and Analysis of Smoldering Multiple Myeloma Patient Samples

    Toronto, Ontario--(Newsfile Corp. - July 6, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces the completion of the laboratory processing and analysis component of its clinical study for TELO's lead prognostic test for smoldering multiple myeloma ("SMM"). The SMM patient samples were provided by the Mayo Clinic in Q1 2022 as part of an ongoing collaboration to evaluate the Company's prognostic technology for multiple myeloma ("MM"). TELO's study results have now been submitted back...

    2022-07-06 8:15 AM EDT
  • Telo Genomics Announces Successful Validation of Its Proprietary Automation Tools for Smoldering Multiple Myeloma

    Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces that it has completed the validation of a suite of proprietary automation tools developed using cutting-edge machine learning, deep machine learning and artificial intelligence technologies to maximize the efficiency and throughput of its technology workflow. The validation was conducted on a subset of smoldering multiple myeloma (SMM) patient samples that were received in collaboration with the Francois Baclesse Cancer Center,...

    2022-05-31 8:45 AM EDT
  • Telo Genomics Announces Investor Relations Agreement and Option Grants

    Toronto, Ontario--(Newsfile Corp. - March 15, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has engaged Tracey Kidd ("Kidd") to perform services related to investor relations activities for the Company, as defined in accordance with the polices of the TSX Venture Exchange ("TSXV") and applicable securities laws.Pursuant to an engagement agreement entered into with Kidd on March 15, 2022 (the "Engagement Agreement"), Kidd will receive a cash monthly fee...

    2022-03-15 8:45 AM EDT
  • Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test

    Toronto, Ontario--(Newsfile Corp. - March 7, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) (the "Company" or "TELO") announces that it has received clinical samples from its collaborator, Mayo Clinic, to conduct the clinical validation of the Company's lead product in development, its TeloView® prognostic test for segregating high risk and low risk smoldering multiple myeloma (SMM) patients. TELO announced on March 28, 2021, that it had completed the feasibility stage of its ongoing clinical studies in...

    2022-03-07 8:45 AM EST
  • Telo Genomics Appoints Dr. McGlennen as Board Director, a Leader in Commercializing Novel Diagnostic Technologies

    Toronto, Ontario--(Newsfile Corp. - February 3, 2022) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that Dr. Ron McGlennen, President and Founder of the medical laboratory Access Genetics, Minnesota, USA, has joined its Board of Directors. Dr. McGlennen brings unique and valuable expertise to TELO's board with extensive experience in successfully introducing novel diagnostics technologies into clinical laboratories across the USA.Dr. McGlennen brings over 30 years of leadership in the development and commercialization of...

    2022-02-03 8:51 AM EST